Can a scientific article be libellous?
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to J R Lewis.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
OBJECTIVE: To report a case of possible levofloxacin-induced bilateral Achilles tendonitis. CASE SUMMARY: An 83-year-old white woman presented to her physician with five days of hemoptysis. She was diagnosed with right lower-lobe pneumonia based on chest X-ray, and levofloxacin 500 mg/d po for 10 days was prescribed. Three days into treatment she began having a variety of adverse effects, including severe nausea, constipation, stomach cramps, and dizziness. Signs of tendonitis began three days after treatment and peaked four days after completion of therapy. Two weeks later, she was treated by her podiatrist with an ankle immobilizer and rest. At her three-week follow-up, she had marked improvement in her pain and bruising; however, her symptoms had not completely resolved. DISCUSSION: Tendonitis and tendon rupture are rare adverse effects of fluoroquinolone antibiotics; there are no reports in the literature of levofloxacin-induced tendonitis. As newer fluoroquinolones become available, the postmarketing studies will become increasingly important to capture the data on rare but serious adverse effects not discovered in the premarketing trials. CONCLUSIONS: To our knowledge, this is the first reported case of tendonitis caused by levofloxacin reported in the literature. Reports have been made, however, to the manufacturer via postmarketing surveillance. As more people are treated with newer fluoroquinolones, the clinical incidence of tendon rupture with these agents may become clearer.
Explore the source record for details and available documents.
Zomepirac sodium (Zomax) is a new orally effective nonopioid analgesic that can relieve mild to severe pain. It is more effective than aspirin or codeine alone and is as effective as analgesic combinations containing codeine or other narcotics. Given orally, zomepirac has provided analgesia comparable with usual intramuscular doses of morphine in postoperative pain. With long-term use, neither tolerance to its analgesic effect nor psychic or physical dependence has been demonstrated. Like aspirin, zomepirac has anti-inflammatory and antipyretic actions and inhibits the synthesis of prostaglandins. Zomepirac is generally well tolerated with both short-term and long-term use; gastrointestinal reactions are the most frequently occurring side effects.